Legato Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Legato Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-7,208	Closed	-$490K	–	230
2017 Q4	$490K	Buy	+7,208	New	+$504K	0.07%	209
2017 Q3	–	Sell	-2,346	Closed	-$220K	–	289
2017 Q2	$220K	Buy	+2,346	New	+$144K	0.09%	188

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Legato Capital Management's CLVS Position: Q1 2018 in Review

Legato Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2018, closing a stake of 7,208 shares — an estimated $490K sold.

Legato Capital Management first reported a position in CLVS in Q2 2017 and held it in 2 quarters. The position peaked at $490K in Q4 2017. 229 funds tracked by Wall St. Rank hold CLVS as of Q1 2018.

Legato Capital Management reported no remaining Clovis Oncology, Inc. position as of Q1 2018 after selling out during the quarter.
Legato Capital Management sold 7,208 Clovis Oncology, Inc. shares in Q1 2018, an estimated $490K.
Legato Capital Management first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 2 quarters.
Legato Capital Management's Clovis Oncology, Inc. position peaked at $490K in Q4 2017.
229 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2018.

Based on Legato Capital Management's 13F filing for Q1 2018, filed 19 Apr 2018.